Trial Profile
A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2023
Price :
$35
*
At a glance
- Drugs Casirivimab/imdevimab (Primary) ; Casirivimab/imdevimab (Primary) ; Elasomeran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors Regeneron Pharmaceuticals
- 09 Jan 2023 Status changed from active, no longer recruiting to completed.
- 07 Feb 2022 Planned End Date changed from 22 Nov 2022 to 25 Nov 2022.
- 07 Feb 2022 Planned primary completion date changed from 29 Dec 2021 to 25 Nov 2022.